Health Infrastructure Accessibility in San Joaquin, CA

The purpose of this study is to assess the health infrastructure and accessibility in San Joaquin, California through the existing conditions of the city, reviewing various cities facing similar conditions, and creating potential solutions or recommendations to be implemented into the city to accommodate growth and overall well-being in the community. Health infrastructure and accessibility is important to every community since it has the ability to influence the quality-of-care individuals are able to receive. When it comes to infrastructure, it is important to determine the underlying health conditions the local population faces and whether the services provided are adequate in serving the population. As for accessibility, many rural, low-income communities such as San Joaquin and a plethora of other communities in Central California face a variety or hurdles to obtain sufficient healthcare. While accessibility can be determined through many factors, this project views accessibility to healthcare through the lens of affordability (cost), distance to medical services, and transportation options to access healthcare, and emergency medical services. All these factors play a large role in determining the accessibility of healthcare for populations located in rural areas around the state and potentially around the country. The purpose of this project is to illustrate the disparity in healthcare access in many rural areas of California and potentially throughout the United States and help bridge the gap between affordable and accessible healthcare in health desolate areas

2018 Research & Innovation Day Program

A one day showcase of applied research, social innovation, scholarship projects and activities.https://first.fanshawec.ca/cri_cripublications/1005/thumbnail.jp

Multicentre randomised double-blind placebo controlled trial of combination vancomycin and cefazolin surgical antibiotic prophylaxis:the Australian surgical antibiotic prophylaxis (ASAP) trial

INTRODUCTION: Resistant Gram-positive organisms, such as methicillin-resistant staphylococci, account for a significant proportion of infections following joint replacement surgery. Current surgical antimicrobial prophylaxis guidelines recommend the use of first-generation or second-generation cephalosporin antibiotics, such as cefazolin. Cefazolin, however, does not prevent infections due to these resistant organisms; therefore, new prevention strategies need to be examined. One proposed strategy is to combine a glycopeptide antibiotic with cefazolin for prophylaxis. The clinical benefit and cost-effectiveness of this combination therapy compared with usual therapy, however, have not been established. METHODS AND ANALYSIS: This randomised, double-blind, parallel, superiority, placebo-controlled, phase 4 trial will compare the incidence of all surgical site infections (SSIs) including superficial, deep and organ/space (prosthetic joint) infections, safety and cost-effectiveness of surgical prophylaxis with cefazolin plus vancomycin to that with cefazolin plus placebo. The study will be performed in patients undergoing joint replacement surgery. In the microbiological sub-studies, we will examine the incidence of SSIs in participants with preoperative staphylococci colonisation (Sub-Study 1) and incidence of VRE acquisition (Sub-Study 2). The trial will recruit 4450 participants over a 4-year period across 13 orthopaedic centres in Australia. The primary outcome is the incidence of SSI at 90 days post index surgery. Secondary outcomes include the incidence of SSI according to joint and microorganism and other healthcare associated infections. Safety endpoints include the incidence of acute kidney injury, hypersensitivity reactions and all-cause mortality. The primary and secondary analysis will be a modified intention-to-treat analysis consisting of all randomised participants who undergo eligible surgery. We will also perform a per-protocol analysis. ETHICS AND DISSEMINATION: The study protocol was reviewed and approved by The Alfred Hospital Human Research Ethics Committee (HREC/18/Alfred/102) on 9 July 2018. Study findings will be disseminated in the printed media, and learnt forums. TRIAL REGISTRATION NUMBER: ACTRN12618000642280

Implementation of an electronic fingerprint-linked data collection system: a feasibility and acceptability study among Zambian female sex workers

International audienc

Noncore Components of the Fission Yeast γ-Tubulin Complex

Relatively little is known about the in vivo function of individual components of the eukaryotic γ-tubulin complex (γ-TuC). We identified three genes, gfh1+, mod21+, and mod22+, in a screen for fission yeast mutants affecting microtubule organization. gfh1+ is a previously characterized γ-TuC protein weakly similar to human γ-TuC subunit GCP4, whereas mod21+ is novel and shows weak similarity to human γ-TuC subunit GCP5. We show that mod21p is a bona fide γ-TuC protein and that, like gfh1Δ mutants, mod21Δ mutants are viable. We find that gfh1Δ and mod21Δ mutants have qualitatively normal microtubule nucleation from all types of microtubule-organizing centers (MTOCs) in vivo but quantitatively reduced nucleation from interphase MTOCs, and this is exacerbated by mutations in mod22+. Simultaneous deletion of gfh1p, mod21p, and alp16p, a third nonessential γ-TuC protein, does not lead to additive defects, suggesting that all three proteins contribute to a single function. Coimmunoprecipitation experiments suggest that gfh1p and alp16p are codependent for association with a small “core” γ-TuC, whereas mod21p is more peripherally associated, and that gfh1p and mod21p may form a subcomplex independently of the small γ-TuC. Interestingly, sucrose gradient analysis suggests that the major form of the γ-TuC in fission yeast may be a small complex. We propose that gfh1p, mod21p, and alp16 act as facultative “noncore” components of the fission yeast γ-TuC and enhance its microtubule-nucleating ability